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ABSTRAK 
PENGENALAN 
Rawatan yang berkesan dan kepatuhan kepada ubatan  adalah faktor penting untuk 
menentukan kejayaan rawatan penyakit glaukoma. Banyak bukti menunjukkan 
penurunan tekanan intraokular (IOP) membantu mencegah and merencat kemusnahan 
saraf optik dan medan penglihatan. 
OBJEKTIF 
Untuk mengenalpasti dan membandingkan kesan penurunan tekanan intraokular dan 
skor kepatuhan kepada ubatan di antara kombinasi tetap dorzolamide/timolol maleate 
(FCDT) dan kombinasi secara berasingan dorzolamide dan timolol XE (NFDT) dalam 
glaukoma sudut terbuka. 
METODOLOGI 
Kajian ini merupakan kajian klinikal terkawal rawak, kumpulan selari dan kajian buta 
satu yang melibatkan 55 orang pesakit glaukoma sudut terbuka. Pesakit disampelkan 
secara rawak kepada kumpulan FCDT yang menerima kombinasi tetap dorzolamide/ 
timolol maleate dan kumpulan NFDT yang menerima kombinasi secara berasingan 
dorzolamide dan timolol XE selama 3 bulan. Pre-kajian pemberian ubat timolol 
dijalankan selama 2 minggu. Tekanan intraokular asas diambil pada waktu pagi. 
Pesakit diberi temujanji pada bulan pertama dan bulan ketiga. Tekanan intraokular 
dan keselamatan ubatan dinilai semasa temujanji. Skor kepatuhan kepada ubatan yang 
mengandungi peratusan ubat titis yang digunakan berdasarkan timbangan berat botol 
ubatan, Skala Kecekapan Diri Terhadap Kepatuhan Ubat Glaukoma dan Skor 
Kepatuhan Ubatan Secara Subjektif. Ia direkodkan semasa temujanji  bulan ketiga. 
xiv 
 
Data dianalisa menggunakan „repeated measures ANOVA‟, ujian T bebas dan ujian 
„Pearson Chi Square‟. 
 
KEPUTUSAN  
Data demografik adalah serupa di antara kumpulan. Kumpulan FCDT dan NFDT 
secara statistik yang signifikan menurunkan tekanan intraokular pada bulan pertama 
dan ketiga dengan  penurunan tekanan  intraokular min pada bulan pertama adalah 4.9 
mmHg dengan 95% interval keyakinan (CI)  (4.0 ke 5.9) dalam FCDT, 4.9 (95% CI 
4.0 ke 5.8) mmHg dalam NFDT, pada bulan ketiga adalah 5.2 ( 95% CI 4.2 ke 6.2) 
mmHg dalam FCDT dan 4.9 ( 95% CI 3.9 ke 5.8) mmHg dalam NFDT. Min 
peratusan perbezaan intraokular pada bulan pertama dan bulan ketiga menunjukkan 
tiada perbezaan signifikan di antara kumpulan rawatan. Tiada perbezaan yang 
signifikan di antara kumpulan dari segi min skor kepatuhan total. 
 
KESIMPULAN 
Kesan penurunan tekanan intraokular dalam kumpulan FCDT adalah setanding 
dengan NFDT. Kedua-duanya menunjukkan penurunan tekanan intraocular yang 
signifikan pada bulan pertama dan ketiga rawatan. Skor kepatuhan total adalah tinggi 
dan standing untuk kedua kumpulan.  
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ABSTRACT 
INTRODUCTION 
The effective treatment and adherence to medication are important factors for 
successful management of glaucoma. Many evidences showed that lowering the IOP 
could prevent and halt the progression of optic nerve damage and visual field loss.  
 
OBJECTIVES 
To determine and compare the pressure lowering effects and adherence score between 
fixed-combination dorzolamide/ timolol maleate (FCDT) and non-fixed combination 
dorzolamide and timolol XE (NFDT) in open angle glaucoma. 
 
METHODS 
This randomised controlled trial, parallel groups and single-blinded study involved 55 
patients of OAG. Patients were randomised to FCDT group who received fixed-
combination dorzolamide/ timolol maleate and NFDT group that received 
concomitant dorzolamide and timolol XE for 3 months. Pre-study run-in timolol was 
given for 2 weeks. Baseline IOP was taken in the morning. Patients were follow-up at 
month 1 and month 3. IOP and safety of medication   were assessed during follow-up. 
The adherence score consists of   percentage of eye drops used based on bottle weight 
measurement, Glaucoma Medication Adherence Self-Efficacy Scale and Subjective 
Drug Adherence Score were recorded at month 3 follow-up. Data were analyzed 
using repeated measures ANOVA, independent t-test Pearson Chi Square test. 
 
xvi 
 
RESULTS 
The demographic data were similar between the groups. FCDT and NFDT were 
statistically significant  reduced  the IOP at month 1 and  month 3 with mean IOP 
reduction at month 1, 4.9  mmHg with 95% confidence interval ( 4.0  to 5.9)  in 
FCDT, 4.9 ( 95% CI  4.0 to 5.8) mmHg  in NFDT, at month 3 were 5.2 ( 95% CI 4.2 
to 6.2) mmHg in FCDT and 4.9 ( 95% CI 3.9 to 5.8) mmHg in NFDT. The mean 
percentage of IOP difference between treatments groups at one month and three 
months were no significant different. There was no significant difference of mean 
total adherence score between the groups.  
 
CONCLUSION 
The pressure lowering effects of fixed-combinations dorzolamide/ timolol maleate 
and non-fixed combination dorzolamide and timolol XE was comparable. Both 
provide a significant reduction of IOP at one month and three months treatment. The 
total adherence score was high in both treatment groups and comparable. 
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CHAPTER 1 
INTRODUCTION 
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CHAPTER 1: INTRODUCTION  
 
1.1 Open angle glaucoma 
1.1.1 Definition of Open Angle Glaucoma (OAG) 
Glaucoma is a progressive optic neuropathy characterised by excavation of optic 
nerve heads and specific patterns of visual field defect. The evidence of optic nerve 
damage derives either from the optic disc or retinal nerve fibre layered structural 
abnormalities or reliable and reproducible visual field abnormality or from both 
(Panel, 2010). As open angle glaucoma, the gonioscopy findings are open anterior 
chamber angles.    
 
There occur multiple factors involved in the pathogenesis of glaucoma. The initial 
insult primary result derived from the elevated intraocular pressure (IOP) and vascular 
dysregulation leads to secondary insult  include excitotoxic damage caused by 
glutamate or glycine released from injured neurons and oxidative damage caused by 
the over-production of nitric oxide (NO) and other reactive oxygen species (Agarwal 
et al., 2009). 
 
Glaucoma has been classified as open angle or closed angle and as primary or 
secondary. Primary open angle glaucoma (POAG) can occur with or without elevation 
of IOP. POAG is open angle glaucoma with elevation of IOP while the category 
consisting of open angle  without elevation of IOP is termed normal tension glaucoma 
(NTG) . 
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1.1.1.1 Definition of Primary Open Angle Glaucoma (POAG) 
 
Primary open-angle glaucoma (POAG) is chronic progressive optic neuropathy with 
characteristic patterns of optic nerve damage and visual field loss with the absence of 
secondary causes (SEAGIG). 
 
POAG is lacks of identifiable contributing factors of the secondary open-angle 
glaucoma such as pigment dispersion in pigmentary glaucoma or exfoliated material 
observed in exfoliation syndrome in an eye with open anterior chamber drainage 
angles on gonioscopy and elevated intraocular pressure (IOP). The Ocular 
Hypertension Treatment Study (OHTS) found an increased risk of the onset of POAG 
was associated with increased age , increased vertical and horizontal cup-disc ratio, 
pattern deviation and IOP at baseline. However, the most powerful predictor is central 
corneal thickness (CCT)  which increases the relative risk of POAG by 81% for every 
40 μm thinner (Kass et al., 2002) .  
 
The diagnosis of glaucoma according to cross sectional prevalence studies is based on 
three levels of evidence (Foster et al., 2002). The highest level of evidence requires 
optic disc abnormalities (VCDR > 97.5
 
th percentile in the normal population) and 
visual field defect compatible with glaucoma. As for second, if the visual field cannot 
be obtained satisfactorily, a severely damaged optic disc ( VCDR >  99.7 th percentile 
of normal population) would be  sufficient  to make a diagnosis. Lastly, if the optic 
disc cannot be examined because of media opacity ( and hence no visual field test is 
possible), an IOP exceeding 99.5 th percentile of  the normal population , or evidence 
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of previous filtering surgery, may be taken as sufficient for the  diagnosis of glaucoma 
(Foster et al., 2002). 
 
The characteristic visual defects are defined as asymmetrical points across  the 
horizontal line, located in the mid-periphery, clustered in the neighbouring test points, 
reproducible on at least two occasions, not explained by any other disease and a valid 
representation of the subject‟s functional status. In severe optic disc damage, these 
principles fail to be applied. Therefore a group of researchers interested in 
psychophysics of glaucoma adopted the glaucoma hemifield test graded „outside 
normal limits‟ using the threshold test strategy with the 24-2 test patterns of the Zeiss-
Humphrey field analyser 2 as a  gold standard of glaucomatous visual field loss 
(Foster et al., 2002). 
 
1.1.1.2 Definition of Normal Tension Glaucoma (NTG) 
 
Normal-tension glaucoma (NTG) is a form of open-angle glaucoma characterized by 
glaucomatous optic disc  and defined type and severity  of  visual field defect with a 
median  IOP of  20 mmHg or less in 10 baseline measurements (Anderson, 2003). 
The diagnosis of NTG is essentially based on the optic nerve and visual field defect of 
glaucoma with diurnal IOP measurement (Deborah Kamal and Hitchings, 1998) . 
Phasing should be performed in order to rule out POAG with diurnal variation.  
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However, NTG has several distinguishing features. As the name implies, NTG 
patients have a higher propensity for optic nerve damage at relatively low levels of 
IOP. There are other IOP independent mechanisms of retinal ganglion cells loss that is 
associated with NTG. These include myopia, older age, vasospasm, ischaemia, 
vascular insufficiency and complex genetic factors disorder that involves genetic, 
epigenetic and environmental factors (Shastry, 2013) 
 
Optic disc examination in NTG exhibited narrower neuroretinal rim particularly 
inferiorly and inferotemporally (Caprioli and Spaeth, 1985).  Other frequent findings 
found in NTG are disc haemorrhage and beta zone peripapillary atrophy, disc 
haemorrhage has significantly poor prognostic indicator (Tezel et al., 1996; Ishida et 
al., 2000). Visual field defects typically appear deeper, steeper and closer to fixation 
in patients with NTG than in patients with POAG (Song and Caprioli, 2014) 
 
The progressive nature of the disease will distinguish the NTG from an isolated optic 
neuropathy such as compressive optic neuropathy, ischaemic optic neuropathy, 
congenital disc abnormality and toxic optic neuropathy. Therefore, clinical 
assessment of systemic comorbidities and brain imaging may be necessary. 
 
Although IOP is within the normal range, it is still postulated that IOP is the risk 
factor in the development and progression of the disease. The Collaborative Normal-
Tension Glaucoma Study (CNTGS) revealed that a 30% reduction in IOP can prevent 
the progression of visual field loss in most patients with previously documented 
progression or a fixation threat(Anderson, 2003). 
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1.1.2 Prevalence of OAG 
 
The estimated number of people with OAG and ACG reached 60.5 million in 2010 
and increased  to 79.6 million people in 2020 (Quigley and Broman, 2006). From the 
estimated number of people with glaucoma, 74% are OAG. South East Asia 
represents 4.7 % (2.1 million) of worldwide OAG (Quigley and Broman, 2006).  
 
The prevalence of POAG reported in population-based studies in Asia range from 
between 0.5% in Hovsgol, Mongolia to 3.9% in Tamiji, Japan (Cho and Kee, 2014). 
Singapore Malay Eye Study (SiMES-1) reported that 3.2% of the study population 
were afflicted with primary open angle glaucoma followed by secondary glaucoma 
(0.8%)  and primary  angle closure glaucoma (0.2%)(Rosman et al., 2012).       
 
However, NTG is most prevalent within the Japanese (3.6%) and Korean (2.04%) 
populations rather than Caucasian inhabitants(0.6%)   
 
Bilateral blindness from OAG comprised 5.8 million people in 2020 in contrast with  
ACG sufferers estimating about 5.2 million (Quigley and Broman, 2006). The number 
of people with glaucoma is estimated to increase to 111.8 million in 2040 on a global 
scale (Tham et al., 2014). This data is imperative for the planning of glaucoma 
screening, treatment and estimated the public health burden. 
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1.2 Treatment of OAG 
1.2.1 Medical treatment 
 
The treatment of glaucoma must be weighted between the risks of therapy and the 
anticipated benefits. Prevention and modification of risk factors particularly the raised 
intraocular pressure is the primary goal of the management of glaucoma. Early 
Manifest Glaucoma Trial (EMGT) reported that a reduction in each  mmHg IOP will 
reduce 10% risk of the visual field defect progression .The study also discovered that 
the predictive factors for glaucoma progression include higher baseline IOP, 
exfoliation, bilateral disease, worse mean deviation, older age and frequent disc 
haemorrhage during follow-up (Leske et al., 2003).  The Ocular Hypertension 
Treatment Study (OHTS) evaluated the safety and efficacy of topical ocular 
hypotensive medication in delaying or preventing the onset of primary open angle 
glaucoma. OHTS found a 22.5% decrease in IOP in the treatment group and 4.0% in  
the control group, this was associated with  a reduction in the development of POAG  
from 9.5%  in controls to 4.4%  in treated patients at 60 months follow-up (Kass et 
al., 2002). There was also evidence proving that reducing the IOP could preserve the 
vision, this was reported by the Collaborative Normal Tension Glaucoma Study 
(CNTGS). The study concluded that by reducing the IOP by at least 30% lowered the 
rate of visual field progression significantly from 35% to 12% (Anderson, 2003) .  
 
Medical treatment of glaucoma can be divided into several groups of ocular   
hypotension based on chemical structure and pharmacologic action. These include: 
 β - adrenergic antagonists 
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  Prostaglandin analog 
 carbonic anhydrase inhibitors 
 parasympathomimetics 
 adrenergic agonist ( selective and non-selective α2- agonist )  
 
There are many factors required for  consideration before initiating the treatment of 
glaucoma, which include selecting the appropriate medication, establishing the target IOP 
and follow-up evaluations to establish efficacy and most important the safety of the 
treatment. The selection of appropriate medication is exceedingly individualised. It is most 
appropriate begin with monotherapy, easier to comply with, less side effects and is 
undeniably more cost effective. 
As the elevated IOP is the vital risk factor for glaucoma development and progression, the 
physicians must establish a target pressure that can prevent further glaucomatous damage. 
The target pressure is based on the status of optic nerve heads and other risk factors 
associated with progression.  
 
 
1.2.1.1 Non-fixed combination treatment 
 
The ocular hypotensive medications can be administered in a non-fixed combination, fixed 
combinations or systemic medication. The non-fixed medication is a single type of ocular 
hypotensive medication that derived from the group mentioned above. Table 1.1 illustrates 
ocular hypotensive medication according to chemical structure. 
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Table 1.1: Ocular hypotensive medications 
 
Table derived from Preferred Practise Pattern Guidelines. Primary Open Angle Glaucoma, 
San Francisco, CA: American Academy of Ophthalmology; 2010. 
.  
Timoptic-XE is a timolol maleate ophthalmic gel forming solution and a non-selective beta-
adrenergic receptor blocking agent. The gel forming solution contains a purified anionic 
heteropolysaccharide derived from gellan gum. Upon contact with the precorneal tear film, 
timoptic-XE forms a gel that is subsequently removed by the flow of tears. 
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Pharmacologically, it reduced IOP by a reduction in aqueous formation. The ocular side 
effects of Timoptic-XE are pain, conjunctivitis, crusting discharge, foreign body sensation, 
itching and tearing. The systemic side effects include headache, dizziness, and upper 
respiratory infection. 
 
Dorzolamide or generic name Trusopt® is a dorzolamide hydrochloride ophthalmic solution 
2%. It is a carbonic anhydrase inhibitor that decreases the aqueous humor secretion. 
Therefore it reduces the intraocular pressure by presumably slowing the formation of 
bicarbonate ion with subsequent reduction in sodium and fluid transport. 
 
The most frequently reported adverse reactions are ocular burning, stinging,and discomfort 
immediately following  the instillation of the eye drops. Approximately one-quarter of 
patients reported a bitter taste, 10-15% developed superficial punctate keratitis and 10% 
experienced symptoms and signs of ocular allergic reaction. Other ocular and systemic 
adverse reactions were reported infrequently, including headaches, nausea, asthenia/fatigue; 
and there occurred rare complication of, skin rashes, urolithiasis and iridocyclitis. 
 
1.2.1.2 Fixed combination medication  
 
In recent years, fixed combination IOP lowering agents has gained its popularity. The fixed 
combinations contain two medications in a single bottle and offer several advantages over 
concurrent medication used. The fixed combination was more convenience, received better 
adherence, reduced exposure to preservative, reduced the effects of  “ washout” when 
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instilling multiple doses and is possibly more cost effective compared to the two separate 
bottles (Bell et al., 2010). 
 
The fixed combination dorzolamide/timolol maleate available as Cosopt® (Merck & Co.Inc.) 
was proved by the Food and Drug Administration (FDA) in 1998. It is a combination of 
dorzolamide 2% and timolol maleate 0.5%. Pharmacologically, it reduced the IOP by 
decreasing aqueous humour production, they tend to have an additive and synergistic effect 
when administered together either as a fixed combination or concomitantly. The ocular side 
effects are the same as for both drugs individually. Table 1.2 represents fixed-combination 
ocular hypotensive medication. The mode of action and side effects are similar to the 
individual drug. Intraocular pressure-lowering effects of commonly used fixed combination 
drugs with timolol in the management of POAG were studied by Ozer M.A et al.  They 
discovered that brinzolamide/ timolol, dorzolamide/timolol and latanaprost/timolol revealed 
analogous lowering efficacies on an IOP level (Ozer M.A et al., 2014). 
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Table 1.2: Fixed combination ocular hypotensive medications. 
Class/compound 
 
Brand 
name 
Dosage Mode of action IOP decrease 
Timolol / 
dorzolamide 
Cosopt bid Decrease aqueous 
production 
 
25% -30% 
Timolol / 
Latanaprost 
Xalacom qd Decrease aqueous 
production and increase 
uveoscleral outflow  
 
Greater than 
monotherapy with each 
individually 
Timolol /  
Travoprost  
DuoTrav qd Decrease aqueous 
production and increase 
uveoscleral  outflow 
   
Same as above 
Timolol / 
Bimatoprost 
Ganfort qd Decrease aqueous 
production and increase 
trabecular and 
uveaoscleral outflow 
 
Same as above 
Timolol / 
brimonidine 
tartrate 
Combigan bid Decrease aqueous 
production and increase 
uveoscleral outflow 
 
Same as above 
 
Table information adapted from American Academy of Ophthalmology: Glaucoma. 2011-
2012  
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1.2.2 Surgical treatment    
 
Surgical treatment for glaucoma is undertaken when medical therapy has failed, not tolerated 
well, is ineffectual and if glaucoma remains uncontrolled with documented progressive 
damage. Trabeculectomy is the gold standard of surgical intervention for POAG. It is a 
creation of fistula between the anterior chamber to the subconjunctival space to providing 
alternative drainage of aqueous outflow.   
 
The use of low dose concentration of mitomycin intraoperatively has favourable outcomes in 
primary glaucoma patients after a 2 years follow-up.(Huang et al., 2013) 
 
The glaucoma drainage device implant should be considered in POAG patients who failed 
trabeculectomy with antifibrotics, patients with inadequate conjunctiva who had undergone 
severe trauma or extensive retinal detachment surgery and patients with associated active 
uveitis, neovascular glaucoma or aphakic eyes. 
 
The Collaborative Initial Glaucoma Treatment Study (CIGTS)   compared initial treatment of 
newly diagnosed open-angle glaucoma with either medications or immediate filtration 
surgery. After 5 years, trabeculectomy lowered IOP marginally more effectively than initial 
medical therapy. Both groups resulted IOP reduction of 37% and the outcome was a very low 
incidence of visual field progression (Lichter et al., 2001). 
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1.3 Intraocular Pressure (IOP) and its measurement 
  
Intraocular pressure is an essential modifiable risk factor in preventing the development and 
progression of glaucoma. The IOP is determined by the balance between the rate of aqueous 
secretion and aqueous outflow. Any circumstances that effect the aqueous humour formation 
and outflow causes changes to the IOP. These include the local and systemic disorders, 
medication and surgeries.   
 
There exist multitudinous methods of IOP measurement. These methods are applanation 
tonometers, indentation tonometers, dyanamic contour tonometer, pneumotonometer (air 
puff) and transpalpebral tonometer. Goldmann  Applanation Tonometer (GAT) is the most 
commonly used and is considered the gold standard of IOP measurement (Yilmaz et al., 
2014). The applanation tonometer system calculates the IOP by measuring the flattened 
corneal area with constant force. However ,Goldmann Applanation Tonometer reading can be 
affected by corneal thickness, corneal curvature, modulus of elasticity (ocular rigidity) and 
tears films (Chihara, 2008). GAT  underestimates the IOP in thin corneas and overestimates 
IOP in thick corneas (ElMallah and Asrani, 2008). 
There are numerous advances in the development of tonometry, such as dynamic contour 
tonometry which measures IOP with less dependence on corneal properties compared to 
GAT. Other convenient and easy to use tonometry is rebound tonometer which can be 
utilized at home and the reading is well correlated with GAT (ElMallah and Asrani, 2008).   
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1.4 Adherence of Medication  
1.4.1 Defination of Adherence                
 Patient adherence was recognised as an imperative tool to effective treatment and successful 
management of the chronic diseases. Adherence to medication is the extent to which a patient 
acts in accordance with the prescribed interval, and dose of a dosing regimen (Cramer et al., 
2008). The term is used interchangeably with compliance to medication. Medication 
persistence refers to the act of continuing the treatment for the prescribed duration or may be 
defined as the duration of time commencing from initiation to discontinuation of therapy 
(Cramer et al., 2008).  Glaucoma medication adherence can be measured in several ways, 
including self- report, pharmacy refill reports, electronic monitoring and direct observation 
(Sleath et al., 2011) .  
 
1.4.2 Measurement of adherence   
The gold standard of monitoring the adherence in glaucoma is by electronic monitoring. 
During a one  month study of adherence, the self- reported adherence was 100%   whereas,  
microchips documented actual adherence of  only  76% (Okeke et al., 2009).  The electronic 
monitoring provides additional information than prescription refill rate or alternative methods 
because it incorporates a time component (Robin et al., 2007). 
 
 Sleath, Blalock et al have developed a Glaucoma Medication Self-efficacy Questionnaire 
which examines  adherence to glaucoma medication and self-confident eye  drops technique. 
They found that the 10 items  Glaucoma Medication  Adherence Self- efficacy Scale was 
significantly associated with the objective electronic measure of adherence (β coefficient 
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8.52%, 95% CI 1.94 to 15.1) .Patients who are expected to be non-adherent will have a lower 
score in the scale (Sleath et al., 2011). 
 
Hong S et al implemented a subjective drug adherence score in their study of patients‟ 
attitudes towards anti-glaucoma medication and their association with adherence. They 
reported that patients with negative approaches towards anti-glaucoma drugs tend to exhibit 
lesser degree adherence than patients with positive attitudes.(Hong et al., 2010). 
 
1.4.3 Factors affecting adherence 
 
Adherence to medication was associated with patient‟s understanding of the disease and 
rationale of the treatment and complexity of the treatment regime. Additional  of second 
medication and complexity of glaucoma therapy was associated with a decrease in adherence 
by increasing intervals until refilling of medication. Many reasons for non-adherence or non-
persistence include cost ,tolerability, difficulty in  administering drops, denial, lack of 
education, forgetfulness, schedule and travel issue (Schwartz and Quigley, 2008) 
 
Study conducting on adherence by Tsai J.C, identified 4 major types of barriers to adherence. 
The barriers are medication regimen, patient factors including the elderly, reduced cognition 
and musculoskeletal problems, provider factors and situational or environment factors (Tsai, 
2009). Okeke et al conducted a study on patients with once a day administered glaucoma 
medication, found that interventional strategies consisting of education and reminder systems 
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improved adherence rates from 54% to 75% . IOP does not correlate with adherence (Okeke 
et al., 2009)  
 
1.5 Rationale Of The Study           
 
There are a few studies which centre on comparing the effectiveness between fixed 
combinations dorzolamide/timolol maleate and non-fixed dorzolamide and timolol maleate 
completed previously.  
 
However, during the course of our study, we compared the effectiveness of fixed 
combinations to the non-fixed of dorzolamide and timolol  XE within our population. We 
would also like to compare the adherence to medication between these 2 groups. We hope 
that this study will assist in improving our management of glaucoma patients. 
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CHAPTER 2: OBJECTIVE 
2.1 General Objective 
To study the effectiveness and adherence of fixed combinations dorzolamide/ timolol maleate 
(FCDT) and non-fixed dorzolamide and timolol XE (NFDT)  in open angle glaucoma. 
  
2.2 Specific Objectives 
2.2.1 To determine the pressure lowering effects of fixed combinations dorzolamide / 
timolol maleate (FCDT) and non-fixed dorzolamide and timolol XE (NFDT)  
2.2.2 To compare the pressure lowering effects of fixed combinations dorzolamide / timolol 
maleate (FCDT) and non-fixed dorzolamide and timolol XE (NFDT) at month 1 and 
month 3 from the baseline. 
2.2.3 To determine the adherence score (i.e Glaucoma Medication Adherence Self-Efficacy 
Scale , bottle weight and subjective drug  adherence  score ) of fixed combinations 
dorzolamide / timolol maleate and non-fixed  dorzolamide and timolol XE. 
2.2.4 To compare the total adherence score to medication of fixed combinations 
dorzolamide / timolol maleate and non-fixed dorzolamide and timolol XE at month 3. 
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CHAPTER 3: METHODOLOGY 
3.1 Study Design 
Randomised, single blinded involving two parallel groups clinical trial. 
 
3.2 Population, location and duration 
 
3.2.1 Study population 
 All patients from Hospital Universiti Sains Malaysia(USM), Kelantan whom fit the inclusion 
criteria. 
 
3.2.2 Study location 
Eye Clinic, Hospital USM, Kota Bharu, Kelantan 
 
3.2.3 Study duration 
 From August 2012 to October 2014 
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3.3 Ethical Approval  
This study was approved by the Research and Ethics Committee (Human)  Universiti  Sains 
Malaysia (USM), Clinical Science Research Platform, USM Health  Campus on  8
th
 August 
2012 ( reference no USMKK/PPP/JEpeM) [252.3(6)] (Appendix E). This study was 
conducted in accordance to Declaration of Helsinki for Human Research. 
  
3.4 Randomisation Method 
Non probability sampling was applied in the study. Block of 4 randomization method was 
used to assign patient into fixed combinations dorzolamide/ timolol maleate (FCDT) group 
and non-fixed combinations dorzolamide and timolol XE (NFDT) group. A randomized 
block size of 4 was chosen, balanced combination of 6 (AABB, ABAB, ABBA, BAAB, 
BABA, BBAA). Block was randomly chosen by using random number 1-6 to determine the 
assignment of all 58 participants. This procedure results in 29 participants in each group. 
 
3.5 Sampling and Sample Size 
3.5.1 Sampling Method 
 All POAG and NTG patients attending glaucoma clinic, HUSM between August 2012 and 
October 2014 who fulfilled the selection criteria were recruited through non-probability 
sampling. 
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3.5.2 Sample size calculation  
1. a) To determine the pressure lowering effect of fixed combination dorzolamide  
and timolol maleate (FCDT)  
 
 Sample size determination using single mean formula 
 n   =    z σ    2    
             Δ  
n = sample size      σ= standard deviation   ∆= precision 
σ  = 3.9 mmHg ( Choudhri S et al ,2000),   Δ = 1.2 mmHg , z = 1.96 
n = 41 
to consider 10 % drop out during the study , (41 + 4),  n = 45 
 
1. b) To determine the pressure lowering effect of non-fixed  dorzolamide and timolol 
meleate  
n   =    z σ    2 
             Δ 
σ  = 4.1 mmHg  ( Chouldri S et al , 2000) , Δ = 1.2 mmHg , z = 1.96 
n = 45 
to consider 10 % drop out during the study , (45 + 5),    n = 50 
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2. a) to compare the pressure lowering effect of fixed combination dorzolamide and   
timolol malaete (FCDT) and non-fixed dorzolamide and timolol XE (NFDT) at  
month 1 
Sample size per group by two mean  formula,    
 n : 2σ2  (Zα  + Zβ )2 
        Δ2  
n = required sample size σ= standard deviation  ∆= precision 
Zα= value of standard normal distribution cutting off probability α  
Zβ= value of standard normal distribution cutting probability β 
Zα = 1.96 for α = 0.05 ( two tailed) ,   zβ = 1.28 for  90% power 
Δ = 3.5 mmHg,  σ = 3.9 mmHg ( Chouldri S et al 2000) 
n = 26 
to consider 10% drop out during the study, (26 + 3) = 29 
therefore sample size for 2 groups are 58  
 
2. b) to compare the pressure lowering effect of fixed combination Dorzolamide and 
timolol malaete (FCDT) and non-fixed Dorzolamide and Timolol XE (NFDT) at 
month 3 
Sample size per group by two mean formula,   
 n : 2σ2  (Zα  + Zβ )2 
        Δ2  
22 
 
Zα = 1.96 for α = 0.05 (two tailed) , zβ = 1.28 for 90% power 
Δ = 3.2 mmHg,  σ = 3.5 mmHg ( Strohmaier K et al, 1998)   
n = 25 
to consider 10% drop out during the study, (25 + 3) = 28 
therefore sample size for 2 groups are 56 
 
3. a)To determine the adherence  to medication of fixed combination Dorzolamide/  
timolol meleate  
Sample size calculation using single proportion formula 
n =    z     
2
 p (1-p) 
         ∆          
n = required sample size,     p= anticipated population proportion,     ∆= absolute precision 
P= 0.9,  α = 0.05% ,  Δ = ± 12 % 
n = 24,  
to consider 10% drop out during the study, ( 24 +2) , n = 26 
 
3. b) To determine the adherence to medication non-fixed dorzolamide and timolol 
XE.  
Sample size using single proportion formula 
n =      z     
2
 p (1-p) 
           ∆            
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P= 0.65,  α = 0.05% ,  Δ = ± 15 % 
n = 38,  
to consider 10% drop out during the study, ( 38+ 4) , n = 42 
 
4.a) To compare the adherence  to medication of fixed combination dorzolamide and 
timolol melaete and non-fixed  dorzolamide and timolol XE.          
 Sample size calculation using two proportions formula  
 n =   P1 ( 1- P1 ) + P2 ( 1-P2 )  ( Zα + Zβ) 
2  
        
                                    ( P1 – P2 )
2
      
n = required sample size,    
Zα= value of standard normal distribution cutting off probabilily α 
Zβ= value of standard normal distribution cutting off probability β     
Zα = 1.96 for α = 0.05 (two tailed),   Zβ = 0.84 for 80% power 
 P1 = 0.65, proportion of adherence to non-fixed glaucoma therapy (pilocarpine, 
QID doses) ( Kass MA et al, 1986) 
  P2 = 0.94, expected proportion of study outcome 
 n = 26     
 to consider 10% drop out during the study, (26+3 =29) 
Therefore, n= 58 
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3.6 Selection Criteria 
3.6.1 Inclusion Criteria 
  Age more than 40 years old  
  Unilateral or bilateral open angle glaucoma, if bilateral eyes were eligible for the 
study the right eye will be chosen. 
 Glaucoma patients who received monotherapy or dual therapy. 
 
3.6.2 Exclusion Criteria 
  Secondary open angle glaucoma 
 Contraindication to use beta blocker antiglaucoma drug such as patient with chronic 
obstructive pulmonary disease, asthma, bradycardia and second and third degree heart 
block 
 IOP more than 35 mmHg on dual therapy during follow-up 
 Known hypersensitivity to any product of investigational product such as 
benzylkonium chloride or sulphonamide. 
 
 
 
 
 
